Literature DB >> 23463238

Novel insights into the biology of interleukin-32.

Leo A B Joosten1, Bas Heinhuis, Mihai G Netea, Charles A Dinarello.   

Abstract

Interleukin (IL)-32 is known as a proinflammatory cytokine that is likely involved in several diseases, including infections, chronic inflammation, and cancer. Since the first report in 2005, IL-32 has been the subject of numerous studies to unravel the biological function of this molecule. For example, silencing of endogenous IL-32 in primary or cell lines of human origin consistently suppressed responses to Toll-like receptors. The protein folding structure of the six isoforms of IL-32 does not resemble that of any classical cytokine and as of this writing, a specific IL-32 receptor has not been identified. Instead, we propose a mechanism by which exposure to extracellular IL-32 or overexpression of the molecule results in binding to intracellular partners that influences functions such as gene expression, cell death, or survival. As such, this review offers insights into the role of IL-32 in several diseases, host defense, inflammation, immune function, and cancer. Finally, possibilities to target IL-32 in several diseases are proposed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463238     DOI: 10.1007/s00018-013-1301-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  71 in total

1.  Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein.

Authors:  Haruki Hasegawa; Heather J Thomas; Ken Schooley; Teresa L Born
Journal:  Cytokine       Date:  2011-01       Impact factor: 3.861

2.  NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy.

Authors:  Mirjam Schenk; Stephan R Krutzik; Peter A Sieling; Delphine J Lee; Rosane M B Teles; Maria Teresa Ochoa; Evangelia Komisopoulou; Euzenir N Sarno; Thomas H Rea; Thomas G Graeber; Soohyun Kim; Genhong Cheng; Robert L Modlin
Journal:  Nat Med       Date:  2012-03-25       Impact factor: 53.440

3.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

4.  Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3.

Authors:  Mi H Park; Min J Song; Min-Chul Cho; Dong C Moon; Do Y Yoon; Sang B Han; Jin T Hong
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

5.  Negative feedback regulation of IL-32 production by iNOS activation in response to dsRNA or influenza virus infection.

Authors:  Wei Li; Fang Yang; Yan Liu; Rui Gong; Li Liu; Yong Feng; Pan Hu; Wei Sun; Qian Hao; Lei Kang; Jianguo Wu; Ying Zhu
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

6.  Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts.

Authors:  Atsushi Nishida; Akira Andoh; Makoto Shioya; Shokei Kim-Mitsuyama; Atsushi Takayanagi; Yoshihide Fujiyama
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-31       Impact factor: 4.052

7.  Proteinase 3-processed form of the recombinant IL-32 separate domain.

Authors:  Sunjong Kim; Siyoung Lee; Erk Her; Suyoung Bae; Jida Choi; Jaewoo Hong; Jun Jaekal; Doyoung Yoon; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  BMB Rep       Date:  2008-11-30       Impact factor: 4.778

Review 8.  Anti-integrin monoclonal antibodies.

Authors:  Adam Byron; Jonathan D Humphries; Janet A Askari; Sue E Craig; A Paul Mould; Martin J Humphries
Journal:  J Cell Sci       Date:  2009-11-15       Impact factor: 5.285

9.  I-TASSER server for protein 3D structure prediction.

Authors:  Yang Zhang
Journal:  BMC Bioinformatics       Date:  2008-01-23       Impact factor: 3.169

10.  Endogenous IL-32 controls cytokine and HIV-1 production.

Authors:  Marcel F Nold; Claudia A Nold-Petry; Gregory B Pott; Jarod A Zepp; Milene T Saavedra; Soo-Hyun Kim; Charles A Dinarello
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.426

View more
  37 in total

1.  c-Jun N-terminal kinase and Akt signalling pathways regulating tumour necrosis factor-α-induced interleukin-32 expression in human lung fibroblasts: implications in airway inflammation.

Authors:  Dagen Li; Dapeng Chen; Xuemei Zhang; Hong Wang; Zixin Song; Wenchun Xu; Yujuan He; Yibing Yin; Ju Cao
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Authors:  Xiuzhang Yu; Bin Zhou; Zhu Zhang; Qianqian Gao; Yanyun Wang; Yaping Song; Yan Pu; Yue Chen; Ruiqi Duan; Lin Zhang; Mingrong Xi
Journal:  Tumour Biol       Date:  2015-02-09

3.  Transcriptional Response of Respiratory Epithelium to Nontuberculous Mycobacteria.

Authors:  Masashi Matsuyama; Andrew J Martins; Shamira Shallom; Olena Kamenyeva; Anuj Kashyap; Elizabeth P Sampaio; Juraj Kabat; Kenneth N Olivier; Adrian M Zelazny; John S Tsang; Steven M Holland
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

4.  Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.

Authors:  Yvette J E Sloot; Katrin Rabold; Thomas Ulas; Dennis M De Graaf; Bas Heinhuis; Kristian Händler; Joachim L Schultze; Mihai G Netea; Johannes W A Smit; Leo A B Joosten; Romana T Netea-Maier
Journal:  Cell Oncol (Dordr)       Date:  2019-06-14       Impact factor: 6.730

5.  Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Authors:  Pedro M M Mesquita; Paula Preston-Hurlburt; Marla J Keller; Nalini Vudattu; Lilia Espinoza; Michelle Altrich; Kathryn Anastos; Kevan C Herold; Betsy C Herold
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

6.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

7.  IL-32α-induced inflammation constitutes a link between obesity and colon cancer.

Authors:  Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Beatriz Ramírez; Victor A Ortega; José Luis Hernández-Lizoain; Jorge Baixauli; Sara Becerril; Fernando Rotellar; Víctor Valentí; Rafael Moncada; Camilo Silva; Javier Salvador; Gema Frühbeck
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

8.  Expression of acidosis-dependent genes in human cancer nests.

Authors:  Toshihiko Fukamachi; Shunsuke Ikeda; Hiromi Saito; Masatoshi Tagawa; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2014-07-11

9.  IL-32γ promotes integrin αvβ6 expression through the activation of NF-κB in HSCs.

Authors:  Hongcan Liu; Xingfei Pan; Hong Cao; Xin Shu; Haixia Sun; Jianxi Lu; Jiayin Liang; Ka Zhang; Fengqin Zhu; Gang Li; Qi Zhang
Journal:  Exp Ther Med       Date:  2017-08-17       Impact factor: 2.447

10.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.